马斯克宏图的下一个篇章：脑机接口，2026年将启动大规模量产，有望解锁人机协同终极形态

Investment Rating - Investment rating: Positive (maintained) [1] Core Insights - Neuralink plans to initiate large-scale production of brain-machine interface devices in 2026, with a focus on automated surgical procedures, which is expected to accelerate the commercialization process [4][14] - The brain-machine interface industry is currently experiencing a high growth phase driven by technological breakthroughs, policy support, and expectations of ecological collaboration with robotics [7][72] - The global brain-machine interface market is projected to grow from approximately $2.94 billion in 2025 to about $12.4 billion by 2034, with a CAGR of 17.35% from 2025 to 2034 [68][72] Summary by Sections Section 1: Neuralink's Large-Scale Production and Technological Advancements - Neuralink is set to start large-scale production in 2026, utilizing a new automated surgical approach that avoids traditional invasive methods [14][15] - The company aims to upgrade its products rapidly over the next three years, with plans to demonstrate the potential for human-AI integration by 2028 [16][20] Section 2: Neuralink as a Leading Company in the Brain-Machine Interface Sector - Neuralink is a unicorn company in the brain-machine interface space, with a valuation of approximately $9 billion and a focus on invasive brain-machine technology [6][34] - The company has completed several human implant surgeries and is expanding its clinical trial applications [34][36] Section 3: Understanding Brain-Machine Interfaces - Brain-machine interfaces (BMIs) allow direct communication between the brain and external devices, functioning as a special communication system [53][54] - The technology is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages and risks [58][59] Section 4: Investment Logic and Beneficiary Stocks - The brain-machine interface industry is at a critical juncture, transitioning from laboratory research to commercialization, with significant market expansion potential [72] - Beneficiary stocks include companies like Sanbo Brain Science, Meihua Medical, and Innovation Medical, which are positioned to gain from the growth of the brain-machine interface sector [72][73]